• Mashup Score: 0
    Research Highlights of the Month – September 2023 - eanpages - 8 month(s) ago

    The EANpages editorial team’s selection of recently published papers of outstanding interest to neurologists for September 2023.

    Source: www.eanpages.org
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of EANeurology
      EANeurology

      📢 EAN's September research highlights cover the following topics: Epilepsy, Alzheimer's, Myasthenia Gravis and Migraines. Click here for more info: https://t.co/AALocAOvcK #ResearchHighlights #Epilepsy #Alzheimers #MyastheniaGravis #Migraine #Research https://t.co/XXc57JWebU

  • Mashup Score: 2
    Efficacy of IV Valproic Acid and Oral Valproic Acid Tapers for the Treatment of Pediatric Headaches in the Emergency Department - 8 month(s) ago

    Background and Objectives Pediatric headaches, including migraine, are a common reason for emergency department (ED) presentation. IV valproic acid (VPA) followed by oral VPA tapers are often used to abort pediatric headache and reduce recurrence, though limited data exist regarding this approach. This study evaluated the effectiveness of IV VPA and oral VPA tapers for the treatment of acute pediatric headaches in the ED in preventing return encounters. Methods This is a retrospective cohort study of patients aged 5–21 years presenting to a tertiary-care pediatric ED from 2010 to 2016 who received IV VPA for headache or migraine. Primary outcomes were ED disposition, percent pain reduction (initial vs 2-hour patient-reported pain score [10-point scale]), and return for acute headache treatment within 1 month. Results A total of 486 ED encounters were included with a median patient age of 15 years; most of them were females (76%, 369/486). Of available pain scores within 2 hours of IV V

    Source: cp.neurology.org
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of NeurologyCP
      NeurologyCP

      According to this study, IV valproic acid is effective for treating pediatric #headache and #migraine in the emergency department setting. Learn more: https://t.co/nLdyEmAzrp https://t.co/qneRjdQTYL

  • Mashup Score: 3
    Variation in Endpoints in FDA Medication Approvals - 8 month(s) ago

    Background and Objective To assess the characteristics and extent of variation of the endpoints used in trials supporting the US Food and Drug Administration (FDA) approval of medications treating migraine. Methods Using the Drugs@FDA online database, we identified novel prescription medications approved by the FDA between January 2001 and September 2022, for migraine with or without aura, for both acute and preventive treatment, and for episodic and chronic presentations. For each medication, we used the most recent FDA-approved labeling to identify indication, mechanism of action, mode of administration, manufacturer, approval year, number of pivotal trials, trial design, and primary endpoints. Results Sixteen FDA-approved medications for the acute or preventive treatment of migraine were supported by 45 pivotal trials. There were 5 primary endpoint types: (1) change in mean monthly migraine days from baseline; (2) change in mean monthly migraine attacks from baseline; (3) change in

    Source: n.neurology.org
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of GreenJournal
      GreenJournal

      This study assessed the characteristics and extent of variation of the endpoints used in trials supporting the US Food and Drug Administration approval of medications treating #migraine. Learn more: https://t.co/C1MZJKsXvv #NeuroTwitter

Load More